(Q36216552)

12 August 2017

1 reference

title

Mechanisms of disease: the impact of antithrombotic therapy in cancer patients (English)

1 reference

12 August 2017

Gloria A Petralia

1

1 reference

12 August 2017

Nick R Lemoine

series ordinal

2

1 reference

12 August 2017

Ajay K Kakkar

series ordinal

3

1 reference

12 August 2017

publication date

1 July 2005

1 reference

Nature Clinical Practice Oncology

12 August 2017

published in

1 reference

12 August 2017

volume

2

1 reference

12 August 2017

issue

7

1 reference

12 August 2017

page(s)

356-363

1 reference

Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Management of thrombosis in cancer: primary prevention and secondary prophylaxis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPONC0225

1 reference

7 January 2021

A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Tissue factor expression correlates with histological grade in human pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Role of tissue factor expression on tumour cell invasion and growth of experimental pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Cross-talk of integrin alpha3beta1 and tissue factor in cell migration

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Role of tissue factor in embryonic blood vessel development.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Regulation of angiogenesis by tissue factor cytoplasmic domain signaling

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Circulating endothelial cells in cancer patients do not express tissue factor

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Clinical implications of circulating angiogenic factors in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Downregulation of tissue factor by RNA interference in human melanoma LOX-L cells reduces pulmonary metastasis in nude mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Coagulation factors VIIa and Xa inhibit apoptosis and anoikis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Thrombin receptor overexpression in malignant and physiological invasion processes

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Thrombin induces neoangiogenesis in the chick chorioallantoic membrane

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate: Final Report of VA cooperative study # 75

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

The effect of low molecular weight heparin on survival in patients with advanced malignancy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Thrombin activatable fibrinolysis inhibitor and its fibrinolytic effect in normal pregnancy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Angiogenesis Inhibition and Tumor Regression Caused by Heparin or a Heparin Fragment in the Presence of Cortisone

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Inhibition of thrombosis in melanoma allografts in mice by endogenous mast cell heparin.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0225

7 January 2021

Identifiers

DOI

10.1038/NCPONC0225

1 reference

12 August 2017

1 reference